Multiple Myeloma Research Foundation

What Multiple Myeloma Research Foundation does

The Multiple Myeloma Research Foundation (MMRF), founded in 1998 and headquartered in Norwalk, Connecticut, is a 501(c)(3) nonprofit organization (Tax ID 06-1504413) and the largest nonprofit in the world solely focused on accelerating a cure for multiple myeloma. The organization operates a vertically integrated research-and-support platform that spans (i) patient services including a Patient Navigation Center, the Myeloma Mentors peer-mentorship program, an Education Resource Hub, a Clinical Trial Finder tool, and financial/transportation assistance; (ii) research infrastructure including the CoMMpass genomic and clinical data repository, the Horizon Clinical Trials Program, and approximately 100 active clinical trials; and (iii) a venture-investing arm, the Myeloma Investment Fund (MIF), which deploys capital into early-stage biotechnology companies developing myeloma-relevant therapies such as bispecific antibodies.

The MMRF's underlying technology stack is built around precision medicine and clinical genomics, with its most differentiated asset being the JAYseq Clinical Whole-Genome Sequencing Test developed over a 15-year collaboration with TGen (part of City of Hope). JAYseq analyzes all 3 billion base pairs of patient DNA and returns comprehensive genomic results in 72 hours, materially faster than conventional genomic workflows. The organization has helped bring 15+ drugs to market, contributed to a 3X increase in multiple myeloma patient life expectancy, and the 5-year relative survival rate for myeloma patients reached 63.7% for the 2016-2022 diagnostic cohort.

The MMRF does not sell products or services; revenue is generated through donations, fundraising events (Walk Program, Marathon/Half Marathon, Road to Victories cycling event — nearly $3 million raised since 2017), corporate sponsorships (Johnson & Johnson sponsors the Road to Victories ride), and investment-related returns from the MIF. The organization serves four primary constituencies: multiple myeloma patients (across all disease stages, including MGUS, smoldering, newly diagnosed, and relapsed/refractory), caregivers and family members, healthcare professionals/researchers, and biopharmaceutical companies. The MMRF has raised over $600 million for research since inception, employs 51-100 staff, and operates primarily in North America with digital distribution (website, webinars, clinical trial finder) extending globally and physical print distribution limited to U.S. addresses.

Name

Multiple Myeloma Research Foundation

Legal name

Multiple Myeloma Research Foundation, Inc.

Website

https://themmrf.org

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit solely focused on accelerating a cure for multiple myeloma. Founded in 1998 in Norwalk, CT, it funds genomic research, supports patients via navigation and mentorship programs, and invests in biotech therapies through its Myeloma Investment Fund.

Ownership category

akta.pro rank

Product category

Nonprofit Cancer Research and Patient Advocacy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Individual and Family Services (624190)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Cancer research funding
• Patient support services
• Genomic testing programs
• Clinical trial matching
• Biotech investment fund

Headquarters

HQ city

Norwalk

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Distribution channels4 records

Marketing channels10 records

Core offering

The Multiple Myeloma Research Foundation (MMRF) is a 501(c)(3) nonprofit that funds multiple myeloma research, accelerates development of next-generation therapies, and delivers patient-facing support services including a Patient Navigation Center, Myeloma Mentors peer mentorship program, Education Resource Hub, and an online Clinical Trial Finder. It also operates the Myeloma Investment Fund (MIF), which makes venture-style investments in biotech companies developing myeloma therapies, and maintains the CoMMpass genomic/clinical data platform to drive precision medicine.

Product overview

The Multiple Myeloma Research Foundation (MMRF) is a nonprofit organization operating as a patient-centered research and support ecosystem rather than a traditional product company. Its core offerings include the Patient Navigation Center providing 1-on-1 support, the Myeloma Mentors peer mentorship program, an Education Resource Hub with multimedia content, a Clinical Trial Finder tool, and the Myeloma Investment Fund (MIF) investing in promising biotech companies. The MMRF also provides comprehensive patient toolkits, runs the Road to Victories fundraising program, and maintains research initiatives like the CoMMpass Database. The organization focuses on accelerating cures through driving novel therapy development, leveraging data for personalized treatment approaches, and empowering patients with information and resources.

Differentiator

Problem solved

Functional benefit

Brands

• Myeloma Investment Fund (MIF): Investment fund that accelerates new therapies for myeloma patients by investing in promising biotechnology companies transforming myeloma treatment.

Products and services

• Patient Navigation Center A support service where patient navigators provide guidance, emotional support, resource connections, and information about multiple myeloma treatments, clinical trials, and care options throughout the patient journey. Targeted at multiple myeloma patients and caregivers in the United States, available by phone (1-888-841-6673), email, and web form, Monday-Friday 9 AM-7 PM ET.
• Myeloma Mentors Program A phone-based peer mentorship service that connects multiple myeloma patients and caregivers with trained patient and caregiver mentors who share personal experiences to inform, empower, and support others in the myeloma community.
• Education Resource Hub An online multimedia resource center featuring webinars, videos, publications, patient toolkits, and educational materials covering multiple myeloma diagnosis, treatment, and care, available in English and Spanish for patients, caregivers, and healthcare providers.
• Clinical Trial Finder An online search and matching tool helping multiple myeloma patients find and connect with appropriate clinical studies investigating new myeloma treatments. Accessible globally via the MMRF website.
• Myeloma Investment Fund (MIF) A venture-style investment vehicle wholly owned by the MMRF that identifies and invests in promising biotechnology companies developing multiple myeloma therapies. The MIF led a $3.1 million financing round for TRIO Pharmaceuticals in 2024 to advance bispecific antibody clinical trials.
• MMRF Patient Toolkit A downloadable bundle of patient guidebooks covering disease overview, newly diagnosed guidance, treatment options, understanding test results, caregiver support, immunotherapy, stem cell transplantation, and financial impact management for multiple myeloma patients and caregivers.
• CoMMpass Database A landmark longitudinal research dataset and access platform collecting genomic and clinical data from multiple myeloma patients, made available to researchers through the MMRF Virtual Lab and credited with advancing breakthrough myeloma diagnostics and treatment approaches.

Quantifiable outcome

• 3X increase in life expectancy for multiple myeloma patients
• +4 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• TGen (Translational Genomics Research Institute) / City of HopecoreStrategic or Co-development Partner · 7 May 202615-year collaboration with TGen, part of City of Hope, led to the development of JAYseq, a clinical whole-genome sequencing test for multiple myeloma patients. The test analyzes all 3 billion base pairs of patient DNA and returns comprehensive genomic results in 72 hours, significantly faster than traditional tests.
• FNIH Biomarkers ConsortiumminorStrategic or Co-development Partner · 30 January 2026The FNIH Biomarkers Consortium marked 20 years of advancing precision medicine. MMRF participates in this consortium which has supported over 20 drug approvals and achieved various regulatory milestones including FDA-qualified surrogate endpoints.
• Johnson & JohnsoncoreGTM or Marketing Partner · 3 November 2025Johnson & Johnson is the sponsor for the MMRF's 9th annual Road to Victories bicycle ride in California's Death Valley (November 5-9, 2025). The event raises funds for multiple myeloma research and involves patients, caregivers, and advocates cycling across desert terrain.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• American Cancer Society: ACS is the largest broad-based cancer nonprofit in the U.S. It competes with MMRF for donor dollars and corporate sponsorships while also funding multiple myeloma research at a much larger scale across all cancer types.
• Susan G. Komen: Komen pioneered the single-disease cancer foundation model with massive fundraising events, research grants, and patient navigation services. It is a broader incumbent that competes with MMRF for major-gift donors and corporate sponsors.
• Stand Up To Cancer (SU2C): SU2C funds collaborative translational cancer research across multiple cancer types, including multiple myeloma. It competes for biopharma co-funding and large-donor attention with a much broader disease mandate than MMRF.

Direct peers

• Cancer Research Institute (CRI): CRI funds immunology-focused cancer research with a venture philanthropy program (Lloyd J. Old STAR program). It competes for the same biopharma partnership and translational research dollars as MMRF.
• V Foundation for Cancer Research: V Foundation funds cancer research through grants and direct investments, including venture philanthropy. It is a direct peer to MMRF's grantmaking and MIF-style biotech investment activities.
• International Myeloma Foundation (IMF): IMF is the other major global nonprofit exclusively focused on multiple myeloma, providing patient education, support groups, and research advocacy. It is the most direct disease-overlap competitor to MMRF.
• The Leukemia & Lymphoma Society (LLS): LLS is the largest nonprofit dedicated to a blood cancer category that includes multiple myeloma. It operates a comparable research-funding, patient-support, and advocacy model, making it the closest direct peer to MMRF.
• Pancreatic Cancer Action Network (PanCAN): PanCAN is a similarly structured single-disease-focused nonprofit that combines research grants, patient services, advocacy, and a venture philanthropy model — directly analogous to MMRF's operating playbook.
• Lustgarten Foundation: Lustgarten is the largest private funder of pancreatic cancer research and operates a research-grant-plus-biotech-investment model that closely mirrors MMRF's grantmaking + MIF structure.
• Damon Runyon Cancer Research Foundation: Damon Runyon funds high-impact cancer research through prestigious fellowships and awards, competing with MMRF for top-tier research talent and biopharma-supported grant programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/theMMRF
• YouTubeyoutube.com/channel/UCQVbiTmG0D6KIt1l49vV6bA
• Facebookfacebook.com/theMMRF
• LinkedInlinkedin.com/company/multiple-myeloma-research-foundation
• Instagraminstagram.com/themmrf

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Multiple Myeloma Research Foundation